Market ExpansionThe approval of the increased dosage from one to three tubes of Ameluz in one treatment session is expected to help expand the market and drive significant sales growth as doctors can treat more surface area for mild to moderate actinic keratosis.
Product DevelopmentBiofrontera reached an important milestone by announcing preliminary results from a Phase 3 study of Ameluz that were highly statistically significant for all primary and secondary endpoints.
Revenue GrowthNew indications for the treatment of superficial Basal Cell Carcinoma and Actinic Keratoses of the extremities are expected to reach the market, which could lead to further acceleration in revenue growth.